Metabolism of Oxyfedrine

Overview

Journal Naunyn Schmiedebergs Arch Pharmacol

Specialty Pharmacology

Date 1972 Jan 1

PMID 4265889

Citations 5

Authors

K Sakai

S Sugano

I Watanabe

M Fukushima

S Takanashi

Y Nishii

Affiliations

Soon will be listed here.

Citing Articles

Noradrenaline depleting effect and metabolism of oxyfedrine in rats.

Appel E, Planz G, Schmid B, Palm D, Grobecker H Naunyn Schmiedebergs Arch Pharmacol. 1973; 280(4):373-90.

PMID: 4274704 DOI: 10.1007/BF00506630.

Effects of oxyfedrine and ouabain on the heart-lung preparation of the dog.

Sakai K, Sugano S, ISONO C Naunyn Schmiedebergs Arch Pharmacol. 1973; 277(1):89-102.

PMID: 4267600 DOI: 10.1007/BF00498787.

The haemodynamic effects of prolonged oral administration of oxyfedrine, a partial agonist at beta-adrenoceptors: comparison with propranolol.

Parratt J Br J Pharmacol. 1974; 51(1):5-13.

PMID: 4155336 PMC: 1776796. DOI: 10.1111/j.1476-5381.1974.tb09625.x.

Excretion of norephedrine by man after oral administration of oxyfedrine.

Appel E, Planz G, Palm D, Grobecker H, STRATMANN D, Donike M Eur J Clin Pharmacol. 1975; 8(3-4):161-6.

PMID: 1233214 DOI: 10.1007/BF00567109.

The dual action of oxyfedrine on cardiac contractility.

Brandt W, Ebner F, Reiter M, Seibel K Naunyn Schmiedebergs Arch Pharmacol. 1979; 309(2):109-17.

PMID: 522897 DOI: 10.1007/BF00501217.

References

RAAB W . THE NONVASCULAR METABOLIC MYOCARDIAL VULNERABILITY FACTOR IN "CORONARY HEART DISEASE". FUNDAMENTALS OF PATHOGENESIS, TREATMENT, AND PREVENTION. Am Heart J. 1963; 66:685-706. DOI: 10.1016/0002-8703(63)90327-2. View

Kirsch U, Flick D, Autenrieth G, von Hymmen D . [Comparative studies on the effect of dipyridamole, oxyfedrine, ajmaline, propranolol and verapamil on the hypothermic fibrillation threshold of guinea pigs]. Arzneimittelforschung. 1969; 19(4):654-6. View

RAAB W . THE NEUROGENIC METABOLIC FACTOR IN ISCHEMIC HEART DISEASE. Dis Chest. 1964; 46:150-7. DOI: 10.1378/chest.46.2.150. View

Niessner H, LUJF A, Moser K . [Experimental studies of the modification of myocardial metabolism with oxyfedrin]. Z Gesamte Exp Med Einschl Exp Chir. 1969; 151(2):163-74. View

Thiele K, Schimassek U, VON SCHLICHTEGROLL A . [New cardioactive beta-aminoketones. Synthesis and considerations on the relationships between pharmacologic effect and constitution of new Mannich bases. I]. Arzneimittelforschung. 1966; 16(8):1064-7. View

Moll A, PETZEL H . [Experimental and clinical studies with a new coronary and heart-active substance]. Z Kreislaufforsch. 1967; 56(1):46-58. View

THIEMER K, Stadler R . [Biochemical studies on L-3-methoxy-omega-(1-hydroxy-1-phenyl-isopropyl-amino)-propiophenone hydrochloride]. Arzneimittelforschung. 1966; 16(11):1502-5. View

Kukovetz W, Poch G . [Stimulation of adrenergic beta-receptors in the heart of normal and reserpinized guinea pigs by oxyfedrine]. Arzneimittelforschung. 1969; 19(9):1562-6. View

KRAUTHEIM J, Schmid E . [Studies on the mechanism of action of a new cardiac beta-aminoketone. Behavior of the metabolism of biogenic amines in humans]. Arzneimittelforschung. 1966; 16(11):1500-2. View

10.

Miller L, BLY C, Watson M, BALE W . The dominant role of the liver in plasma protein synthesis; a direct study of the isolated perfused rat liver with the aid of lysine-epsilon-C14. J Exp Med. 1951; 94(5):431-53. PMC: 2180336. DOI: 10.1084/jem.94.5.431. View

11.

Dux A, Hahn N, Felix R, DRAZNIN N, Meuser H . [Effect of oxyfedrine on the blood flow of coronary vessels in intra- and extramural regions (studies on the dog)]. Arzneimittelforschung. 1969; 19(3):300-4. View

12.

Sakai K . Beta-adrenergic blocking property of l-3-methoxy-omega-(1-hydroxy-1-phenylisopropylamino)-propiophenone-HCL (D 563) in femoral circulation. Jpn J Pharmacol. 1970; 20(2):306-7. DOI: 10.1254/jjp.20.306. View

13.

Sansone M, DELLOMODARME G, Sorrentino L . [CORONARY-DILATING ACTIVITY OF BETA-PHENYLPROPIOPHENONIC DERIVATIVES]. Arch Ital Sci Farmacol. 1963; 13:249-52. View

14.

Somani P, Laddu A . Blockade of cardiac effects of isoproterenol by 4-(2-hydroxy-3-isopropylaminopropoxy)-acetanilide (ICI 50,172). J Pharmacol Exp Ther. 1969; 170(1):72-8. View

15.

STERNITZKE N, Kohler J, Lang E . [The effect of ildamen, a cardio-energetic coronary therapeutic agent, on cardiovascular dynamics]. Med Welt. 1966; (36):1910-5. View